Cargando…
The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745009/ https://www.ncbi.nlm.nih.gov/pubmed/35010673 http://dx.doi.org/10.3390/ijerph19010413 |
_version_ | 1784630242275491840 |
---|---|
author | Sienkiewicz, Kamila Burzyńska, Monika Rydlewska-Liszkowska, Izabela Sienkiewicz, Jacek Gaszyńska, Ewelina |
author_facet | Sienkiewicz, Kamila Burzyńska, Monika Rydlewska-Liszkowska, Izabela Sienkiewicz, Jacek Gaszyńska, Ewelina |
author_sort | Sienkiewicz, Kamila |
collection | PubMed |
description | All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug-related problems. The main role of the aforementioned system is to collect and analyze adverse drug reaction reports. Legislation introduced several years ago allowed patients, their legal representatives and caregivers to report adverse drug reactions, which caused them to be an additional source of safety data. This paper presents the analysis of EudraVigilance data related to adverse drug reactions provided by patients, their representatives, as well as those obtained from healthcare professionals related to medicines which belong to M01A anti-inflammatory and antirheumatic products, a non-steroid group. The objective of the study was to identify the changes in the number and structure of adverse reaction reporting after the introduction of pharmacovigilance (PV) obligations in EU. A review of scientific literature was also conducted to assess the differences in adverse reactions reported by patients or their representatives and by healthcare professionals. We also identified other factors which, according to literature review, influenced the number of adverse reaction reports provided by patients. Analysis of data collected from the EudraVigilance showed that from 2011 to 2013 the number of reports made by patients and their caregivers increased by approx. 24 percentage points, and then, from 2014, it constituted around 30% of the total of reported reactions every year, so patient reporting is an important part of pharmacovigilance system and a source of drugs’ safety information throughout their use in healthcare practice. Additionally, there was no interrelationship between the seriousness of reported adverse reactions and the overall number of patient reports when compared to reports form healthcare professionals. |
format | Online Article Text |
id | pubmed-8745009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87450092022-01-11 The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process Sienkiewicz, Kamila Burzyńska, Monika Rydlewska-Liszkowska, Izabela Sienkiewicz, Jacek Gaszyńska, Ewelina Int J Environ Res Public Health Article All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug-related problems. The main role of the aforementioned system is to collect and analyze adverse drug reaction reports. Legislation introduced several years ago allowed patients, their legal representatives and caregivers to report adverse drug reactions, which caused them to be an additional source of safety data. This paper presents the analysis of EudraVigilance data related to adverse drug reactions provided by patients, their representatives, as well as those obtained from healthcare professionals related to medicines which belong to M01A anti-inflammatory and antirheumatic products, a non-steroid group. The objective of the study was to identify the changes in the number and structure of adverse reaction reporting after the introduction of pharmacovigilance (PV) obligations in EU. A review of scientific literature was also conducted to assess the differences in adverse reactions reported by patients or their representatives and by healthcare professionals. We also identified other factors which, according to literature review, influenced the number of adverse reaction reports provided by patients. Analysis of data collected from the EudraVigilance showed that from 2011 to 2013 the number of reports made by patients and their caregivers increased by approx. 24 percentage points, and then, from 2014, it constituted around 30% of the total of reported reactions every year, so patient reporting is an important part of pharmacovigilance system and a source of drugs’ safety information throughout their use in healthcare practice. Additionally, there was no interrelationship between the seriousness of reported adverse reactions and the overall number of patient reports when compared to reports form healthcare professionals. MDPI 2021-12-31 /pmc/articles/PMC8745009/ /pubmed/35010673 http://dx.doi.org/10.3390/ijerph19010413 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sienkiewicz, Kamila Burzyńska, Monika Rydlewska-Liszkowska, Izabela Sienkiewicz, Jacek Gaszyńska, Ewelina The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process |
title | The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process |
title_full | The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process |
title_fullStr | The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process |
title_full_unstemmed | The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process |
title_short | The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process |
title_sort | importance of direct patient reporting of adverse drug reactions in the safety monitoring process |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745009/ https://www.ncbi.nlm.nih.gov/pubmed/35010673 http://dx.doi.org/10.3390/ijerph19010413 |
work_keys_str_mv | AT sienkiewiczkamila theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT burzynskamonika theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT rydlewskaliszkowskaizabela theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT sienkiewiczjacek theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT gaszynskaewelina theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT sienkiewiczkamila importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT burzynskamonika importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT rydlewskaliszkowskaizabela importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT sienkiewiczjacek importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess AT gaszynskaewelina importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess |